<DOC>
	<DOCNO>NCT00612911</DOCNO>
	<brief_summary>Using bone marrow mononuclear cell 24 patient Idiopathic dilate cardiomyopathy</brief_summary>
	<brief_title>Cell Therapy Dilated Cardiomyopathy : Observational Study</brief_title>
	<detailed_description>Patients Idiopathic dilate cardiomyopathy class II IV NYHA ejection fraction &lt; 35 % select phase I clinical trial bone marrow mononuclear cell delivery coronary artery follow 6 month</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<criteria>Diagnosis idiopathic dilate cardiomyopathy Optimized therapy idiopathic dilate cardiomyopathy Left ventricular ejection fraction ( Simpson ) &lt; 35 % Peak oxygen consumption ( VO2 peak ) &lt; 16 mL.kg1min1 Functional class IIIV NYHA dilate cardiopathy ischemic chagasic origin primary valve disease excessive use alcohol illicit drug pregnancy ventricular arrhythmias comorbidity impact survival</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>